Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Spyre Therapeutics Inc SYRE

Healthcare Biotechnology
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD... see more

Recent & Breaking News (NDAQ:SYRE)

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

GlobeNewswire November 4, 2025

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

GlobeNewswire October 29, 2025

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

GlobeNewswire October 24, 2025

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

GlobeNewswire October 15, 2025

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

GlobeNewswire October 13, 2025

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

GlobeNewswire October 13, 2025

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025

GlobeNewswire October 5, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire October 3, 2025

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases

GlobeNewswire September 15, 2025

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

PR Newswire June 17, 2025

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

PR Newswire June 16, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire June 6, 2025

Spyre Therapeutics to Participate in Upcoming June Investor Conferences

PR Newswire May 28, 2025

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

PR Newswire May 8, 2025

Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001

PR Newswire May 5, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire May 2, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire April 4, 2025

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

PR Newswire March 27, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

PR Newswire March 7, 2025

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

PR Newswire February 27, 2025

Podcasts